Financials data is unavailable for this security.
View more
Year on year Zhejiang Ausun Pharmaceutical Co Ltd grew revenues 6.83% from 764.55m to 816.77m while net income improved 7.87% from 235.38m to 253.90m.
| Gross margin | 55.25% |
|---|---|
| Net profit margin | 32.55% |
| Operating margin | 37.51% |
| Return on assets | 9.13% |
|---|---|
| Return on equity | 12.39% |
| Return on investment | 12.03% |
More ▼
Cash flow in CNYView more
In 2023, Zhejiang Ausun Pharmaceutical Co Ltd increased its cash reserves by 92.99%, or 524.25m. Cash Flow from Financing totalled 469.93m or 57.53% of revenues. In addition the company generated 221.85m in cash from operations while cash used for investing totalled 175.47m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 2.80 |
|---|---|
| Tangible book value per share | 2.62 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.74 |
|---|---|
| Quick ratio | 2.16 |
| Total debt/total equity | 0.144 |
|---|---|
| Total debt/total capital | 0.1259 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 61.25% and 2.33%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 0.46% |
|---|---|
| Div growth rate (5 year) | 50.48% |
| Payout ratio (TTM) | 27.97% |
| EPS growth(5 years) | 38.75 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -1.30 |
More ▼
